論文・技術情報追加のお知らせ

1. Adverse reactions of immune checkpoint inhibitors combined with acetaminophen/non-steroidal anti-inflammatory drugs (NSAIDs): a pharmacovigilance analysis of drug-drug interactions.

ICIと解熱鎮痛薬併用での相互作用シグナルのFAERS解析。

対象DB：FAERS

2. Metformin-associated diarrhea in FAERS: a structured pharmacovigilance study with long-term temporal consistency assessment.

メトホルミン関連下痢のFAERS不均衡分析と長期傾向評価。

対象DB：FAERS

3. Belumosudil-associated neurological adverse events: evidence from FAERS and experimental validation.

ベルモスジル関連神経系副作用のFAERS解析および実験的検証。

対象DB：FAERS

4. Timing between public safety signals and label strengthening in targeted oncology therapies.

分子標的抗がん剤の公的安全性シグナルと添付文書改訂期間。

対象DB：FAERS

5. An update on post-marketing safety signals of sugammadex: A retrospective pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS).

スガマデクスの市販後安全性シグナルに関するFAERS解析。

対象DB：FAERS

6. Taxanes versus platinum derivatives for ovarian cancer: a comparative disproportionality analysis using the FDA adverse event reporting system database.

卵巣がんにおけるタキサン系対白金製剤の副作用不均衡分析。

対象DB：FAERS

7. Ocular Adverse Events Associated with Docetaxel and Paclitaxel: A Pharmacovigilance Disproportionality Analysis.

ドセタキセルおよびパクリタキセル関連眼有害事象の分析。

対象DB：FAERS

8. Characterizing the Thrombotic Spectrum and Clinical Phenotypes of Tranexamic Acid-Associated Adverse Events: A Pharmacovigilance Study Based on the FAERS Database.

トラネキサム酸関連血栓症の臨床フェノタイプとFAERS解析。

対象DB：FAERS

9. The Real-World Safety Profile of Haloperidol: A Comprehensive Pharmacovigilance Analysis Using the Large-Scale FAERS Database.

ハロペリドールのリアルワールド安全性に関する多国籍評価。

対象DB：FAERS

10. Sirolimus-based immunosuppression and reported rejection or death in heart transplant recipients using the U.S. Food and Drug Administration Adverse Event Reporting System.

心移植患者におけるシロリムス免疫抑制と拒絶・死亡の関連。

対象DB：FAERS

11. Safety profile of IL-23 inhibitors from the perspective of physicians and pharmacists: A retrospective real-world pharmacovigilance observational study based on the FAERS database.

IL-23阻害薬の長期安全性に関する医師・薬剤師の評価調査。

対象DB：FAERS

12. Psychosis as an Adverse Effect of Antibiotics in Children and Adolescents.

小児・思春期における抗菌薬誘発性精神病の自発報告分析。

対象DB：FAERS

13. Antifungal ototoxicity, itraconazole, and approaches to its mitigation: a review of a sparse evidence base.

抗真菌薬イトラコナゾールの耳毒性リスクと軽減策の概説。

対象DB：FAERS

14. Distinct Patterns and Earlier Onset of Adverse Events in Young vs. Non-Young Breast Cancer Patients: A Real-World Analysis.

若年乳がん患者における全身療法副作用と発現時期の解析。

対象DB：FAERS

15. Risk of hyperglycemia with different statins by type and dose: a network meta-analysis and real-world pharmacovigilance study.

スタチンの種類および用量別の高血糖リスクに関する解析。

対象DB：FAERS

16. Safety of lecanemab in real-world patients with Alzheimer's disease: a prospective, observational case series supported by FAERS signal analysis.

実臨床におけるアルツハイマー病薬レカネマブの前向き評価。

対象DB：FAERS

17. Disproportionality analysis of adverse event reporting with aspirin, statins, and their co-exposure in FAERS, 2004-2025.

アスピリンとスタチンの単剤・併用時における有害事象比較。

対象DB：FAERS

18. Age-stratified signals and early onset of adverse events with pregabalin: a disproportionality analysis of the FDA adverse event reporting system.

プレガバリン関連有害事象の年齢層別シグナルと発現時期。

対象DB：FAERS

19. Efficacy and safety of nafamostat mesilate for anticoagulation during ECMO/CRRT: insight from the integrated meta-analysis and FAERS pharmacovigilance study.

ECMO/CRRT時の抗凝固におけるナファモスタット評価。

対象DB：FAERS

20. Association of different piperacillin/tazobactam ratios and dosages with the risk of hypokalemia: a propensity score-matched retrospective cohort study.

ピペラシリン/タゾバクタムの配合比と低カリウム血症リスク。

対象DB：FAERS

21. Ensemble signal detection reveals target-specific temporal risk of hypokalemia after immune checkpoint inhibition: a translational pharmacology framework.

ICI療法に伴う低カリウム血症リスクの機械学習検出モデル。

対象DB：FAERS,VigiBase

22. Immune-effector and infection-associated reporting patterns of CD20xCD3 bispecific antibodies in B-cell lymphoma: a label-anchored FAERS analysis with descriptive JADER contextualization.

CD20xCD3二重特異性抗体の免疫毒性および感染症解析。

対象DB：JADER

23. Treatment context is associated with thrombocytopenia report phenotypes in lung cancer: an active-comparator analysis of FAERS and JADER.

肺がんICI治療における血小板減少症報告の背景要因解析。

対象DB：JADER

24. Unintentional Incorrect Route of Drug Administration: An Analysis of Spontaneous Reports of Medication Errors in Children and Adolescents from Germany.

意図しない薬剤誤投与経路に関する自発報告傾向の要因分析。

対象DB：EudraVigilance

25. EudraScore: Modification of the Vigi4Eudra-score for the Assessment of the Completeness of Adverse Drug Reaction Reports in EudraVigilance.

自発報告の完全性を評価するEudraScoreツールの検証。

対象DB：EudraVigilance

26. Small Molecules Prescribed On- and Off-Label for Thoracic Cancers During Pregnancy: A Combined VigiBase and Systematic Review Analysis.

妊娠中の胸部悪性腫瘍に対する低分子標的薬の使用実態調査。

対象DB：VigiBase

27. Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal.

ファーマコビジランスにおける症例特定枠組みの構築と考察。

対象DB：VigiBase

28. Proportionate and disproportionate reporting of different infectious complications of disease modifying therapy in multiple sclerosis.

PML発症患者におけるその他感染性合併症の報告傾向比較。

対象DB：VigiBase

29. In-Hospital Outcomes of Acyclovir With or Without Corticosteroid for Herpes Simplex Encephalitis: A Nationwide Retrospective Cohort Study.

単純ヘルペス脳炎でのアシクロビル・ステロイド併用効果。

対象DB：DPC

30. Association of Prophylactic Abdominal Drain Placement With Short-Term Postoperative Outcomes After Hepatectomy: A Nationwide Inpatient Database Study in Japan.

肝切除術後の予防的腹腔ドレーン留置と短期術後転帰の評価。

対象DB：DPC

31. Patient characteristics and the safety of stent placement for malignant vena cava syndrome in Japan: a nationwide analysis.

悪性大静脈症候群に対するステント留置の患者背景と安全性。

対象DB：DPC

32. Trends in Oral Anticoagulant Prescribing for Atrial Fibrillation and Active Cancer in UK Primary Care.

心房細動を併発したがん患者における抗凝固薬処方動向解析。

対象DB：CPRD

33. Decoding Atrial Fibrillation Heterogeneity: A Nationwide Phenome-Wide Association Study in England.

心房細動の不均一性を解明する全国フェノムワイド関連解析。

対象DB：CPRD

34. Characterising patients in England with Down syndrome and Alzheimer's disease: a descriptive observational study using data from Clinical Practice Research Datalink linked to Hospital Episode Statistics.

英国のダウン症併存アルツハイマー病患者の臨床像と受療動向。

対象DB：CPRD

35. Association Between Systemic Fluoroquinolones and Risk of Peripheral Neuropathy.

経口・全身性キノロン系抗菌薬と末梢神経障害リスクの検証。

対象DB：CPRD

36. Incident Comorbid Diabetes and Outcomes in Multiple Sclerosis: An English Population-Based Cohort Study.

多発性硬化症患者での糖尿病併発による入院・死亡リスク。

対象DB：CPRD

37. Long-Term Inhaled Corticosteroid Use and the Risk of Open-Angle Glaucoma in Patients with Chronic Obstructive Pulmonary Disease.

COPD患者における吸入ステロイド使用と開放隅角緑内障。

対象DB：CPRD

38. Development and external validation of a risk prediction tool for recurrent wheeze attacks in preschool children in England.

就学前小児における反復性喘鳴リスク予測ツールの外部検証。

対象DB：CPRD

39. Exercise, physical activity, and physical fitness in psoriasis and psoriatic arthritis: an umbrella review.

乾癬・乾癬性関節炎患者における運動・身体活動のレビュー。

対象DB：KAERS

40. Early Rhythm Control vs Usual Care After Acute Ischemic Stroke in Patients With Atrial Fibrillation.

心房細動合併脳梗塞後の早期洞調律維持療法と標準治療比較。

対象DB：DeSC

41. Retinal Disease Risk With Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Versus Long-Acting Erythropoiesis-Stimulating Agents in Patients With Non-Dialysis Chronic Kidney Disease: A Real-World Database Analysis in Japan.

HIF-PH阻害薬投与に伴う網膜疾患リスクの全国コホート。

対象DB：DeSC